OBJECTIVE: To examine trends in osteoporosis drug prescribing after hip fracture from 1995 to 2004. METHODS: We conducted a population-based study of enrollees in the Pennsylvania Pharmaceutical Assistance Contract for the Elderly. Hip fractures were identified using Medicare hospital claims between January 1, 1995, and June 30, 2004. Osteoporosis treatment comprised oral bisphosphonates, calcitonin, hormone therapy, raloxifene, and/or teriparatide. Kaplan-Meier methods were used to estimate the probability of treatment within 6 months of fracture, censoring patients on their date of death or 6 months postfracture. RESULTS: Treatment within 6 months after hip fracture improved from 7% in 1995 to 31% in 2002, and then remained stable through 2004. Similar patterns were observed among new users, with treatment increasing from 4% in 1995 to 17% in 2002, with no subsequent increase through 2004. Bisphosphonates led other treatments in the frequency of prescribing, except during 1997-99, when calcitonin was the most common. Among women, hormone therapy prescribing decreased from 22% of those treated in 1995 to 4% in 2004, and raloxifene prescribing remained relatively constant (4%-10%) since its introduction (p for trend = 0.15). Of patients treated before and after hip fracture, 18% changed therapy postfracture. Significantly more patients changed therapy following fracture if a different physician prescribed treatment (26%) compared to those treated by the same physician pre- and postfracture (13%; p < 0.0001). CONCLUSION: Prescribing practices changed substantially over the 10 years of study. The proportion of hip fracture patients treated with osteoporosis drugs has increased, but remains low, with fewer than one-third receiving pharmacotherapy.
OBJECTIVE: To examine trends in osteoporosis drug prescribing after hip fracture from 1995 to 2004. METHODS: We conducted a population-based study of enrollees in the Pennsylvania Pharmaceutical Assistance Contract for the Elderly. Hip fractures were identified using Medicare hospital claims between January 1, 1995, and June 30, 2004. Osteoporosis treatment comprised oral bisphosphonates, calcitonin, hormone therapy, raloxifene, and/or teriparatide. Kaplan-Meier methods were used to estimate the probability of treatment within 6 months of fracture, censoring patients on their date of death or 6 months postfracture. RESULTS: Treatment within 6 months after hip fracture improved from 7% in 1995 to 31% in 2002, and then remained stable through 2004. Similar patterns were observed among new users, with treatment increasing from 4% in 1995 to 17% in 2002, with no subsequent increase through 2004. Bisphosphonates led other treatments in the frequency of prescribing, except during 1997-99, when calcitonin was the most common. Among women, hormone therapy prescribing decreased from 22% of those treated in 1995 to 4% in 2004, and raloxifene prescribing remained relatively constant (4%-10%) since its introduction (p for trend = 0.15). Of patients treated before and after hip fracture, 18% changed therapy postfracture. Significantly more patients changed therapy following fracture if a different physician prescribed treatment (26%) compared to those treated by the same physician pre- and postfracture (13%; p < 0.0001). CONCLUSION: Prescribing practices changed substantially over the 10 years of study. The proportion of hip fracturepatients treated with osteoporosis drugs has increased, but remains low, with fewer than one-third receiving pharmacotherapy.
Authors: Laura-Mae Baldwin; Walter Adamache; Carrie N Klabunde; Kevin Kenward; Celia Dahlman; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Stephen F Hodgson; Nelson B Watts; John P Bilezikian; Bart L Clarke; T Kenney Gray; David W Harris; C Conrad Johnston; Michael Kleerekoper; Robert Lindsay; Marjorie M Luckey; Michael R McClung; Howard R Nankin; Steven M Petak; Robert R Recker Journal: Endocr Pract Date: 2003 Nov-Dec Impact factor: 3.443
Authors: Maria-Teresa Cuddihy; Sherine E Gabriel; Cynthia S Crowson; Elizabeth J Atkinson; Claudia Tabini; W Michael O'Fallon; L Joseph Melton Journal: Arch Intern Med Date: 2002-02-25
Authors: Susan B Jaglal; June Carroll; Gillian Hawker; Warren J McIsaac; Liisa Jaakkimainen; Suzanne M Cadarette; Cathy Cameron; Dave Davis Journal: Can Fam Physician Date: 2003-04 Impact factor: 3.275
Authors: Sumit R Majumdar; Brian H Rowe; Deb Folk; Jeffrey A Johnson; Brian H Holroyd; Donald W Morrish; Walter P Maksymowych; Ivan P Steiner; Charles H Harley; Brian J Wirzba; David A Hanley; Sandra Blitz; Anthony S Russell Journal: Ann Intern Med Date: 2004-09-07 Impact factor: 25.391
Authors: Wojciech P Olszynski; K Shawn Davison; Jonathan D Adachi; Jacques P Brown; Steven R Cummings; David A Hanley; Steven P Harris; Anthony B Hodsman; David Kendler; Michael R McClung; Paul D Miller; Chui Kin Yuen Journal: Clin Ther Date: 2004-01 Impact factor: 3.393
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan Journal: JAMA Date: 2003-06-25 Impact factor: 56.272
Authors: Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak Journal: Endocr Pract Date: 2010 Nov-Dec Impact factor: 3.443
Authors: S M Cadarette; J N Katz; M A Brookhart; T Stürmer; M R Stedman; R Levin; D H Solomon Journal: Osteoporos Int Date: 2009-03-06 Impact factor: 4.507
Authors: Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak Journal: Endocr Pract Date: 2010 Nov-Dec Impact factor: 3.443
Authors: Lee A Jennings; Andrew D Auerbach; Judith Maselli; Penelope S Pekow; Peter K Lindenauer; Sei J Lee Journal: J Am Geriatr Soc Date: 2010-04 Impact factor: 5.562